New CAR-T therapy aims to control Hard-to-Treat lymphoma
NCT ID NCT07360288
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called TC011 for adults with follicular lymphoma that has come back or not responded to at least two prior therapies. TC011 is a type of CAR-T cell therapy that targets cancer cells. The main goal is to see how many patients' tumors shrink or disappear after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug cocktail replace chemo for follicular lymphoma?
- New drug combo aims to outsmart recurring lymphoma
- New combo pill attack aims to control blood cancers
- Smart blood pressure cuffs could protect cancer patients from heart risks
- New cell therapy CT1182 takes on tough lymphoma
- New hope for Tough-to-Treat lymphoma: experimental drug combo enters phase 3 trial